The average one-year price target for Agios Pharmaceuticals (NasdaqGS:AGIO) has been revised to $39.20 / share. This is an increase of 19.62% from the prior estimate of $32.77 dated December 18, 2025.
The price target is an average of many targets provided by analysts. The latest targets range from a low of $28.28 to a high of $65.10 / share. The average price target represents an increase of 41.00% from the latest reported closing price of $27.80 / share.
What is the Fund Sentiment?
There are 471 funds or institutions reporting positions in Agios Pharmaceuticals. This is an decrease of 1 owner(s) or 0.21% in the last quarter. Average portfolio weight of all funds dedicated to AGIO is 0.16%, an increase of 10.85%. Total shares owned by institutions increased in the last three months by 2.47% to 70,749K shares. 
The put/call ratio of AGIO is 0.34, indicating a bullish outlook.
What are Other Shareholders Doing?
Farallon Capital Management holds 5,781K shares representing 9.91% ownership of the company. In its prior filing, the firm reported owning 5,767K shares , representing an increase of 0.24%. The firm increased its portfolio allocation in AGIO by 14.78% over the last quarter.
Bellevue Group holds 3,715K shares representing 6.37% ownership of the company. In its prior filing, the firm reported owning 3,590K shares , representing an increase of 3.35%. The firm increased its portfolio allocation in AGIO by 17.72% over the last quarter.
Erste Asset Management holds 2,765K shares representing 4.74% ownership of the company. In its prior filing, the firm reported owning 2,326K shares , representing an increase of 15.86%. The firm increased its portfolio allocation in AGIO by 61.12% over the last quarter.
Paradigm Biocapital Advisors holds 2,674K shares representing 4.58% ownership of the company. In its prior filing, the firm reported owning 1,143K shares , representing an increase of 57.27%. The firm increased its portfolio allocation in AGIO by 88.11% over the last quarter.
Wellington Management Group Llp holds 2,471K shares representing 4.24% ownership of the company. In its prior filing, the firm reported owning 422K shares , representing an increase of 82.92%. The firm decreased its portfolio allocation in AGIO by 3.56% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
